Curious about HealthEquity (HQY) Q1 Performance? Explore Wall Street Estimates for Key Metrics

29.05.25 15:15 Uhr

Werte in diesem Artikel
Aktien

87,50 EUR -2,50 EUR -2,78%

Wall Street analysts expect HealthEquity (HQY) to post quarterly earnings of $0.81 per share in its upcoming report, which indicates a year-over-year increase of 1.3%. Revenues are expected to be $321.13 million, up 11.7% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.Bearing this in mind, let's now explore the average estimates of specific HealthEquity metrics that are commonly monitored and projected by Wall Street analysts.The consensus among analysts is that 'Revenue- Service' will reach $119.18 million. The estimate suggests a change of +0.8% year over year.The average prediction of analysts places 'Revenue- Custodial' at $151.45 million. The estimate indicates a year-over-year change of +24.5%.Analysts expect 'Revenue- Interchange' to come in at $49.71 million. The estimate points to a change of +4.1% from the year-ago quarter.Analysts predict that the 'Total HSA Assets' will reach $32.13 billion. Compared to the present estimate, the company reported $27.28 billion in the same quarter last year.It is projected by analysts that the 'Total HSA investments' will reach $14.46 billion. The estimate is in contrast to the year-ago figure of $11.43 billion.The collective assessment of analysts points to an estimated 'CDBs Accounts' of 6.86 million. Compared to the present estimate, the company reported 6.91 million in the same quarter last year.The consensus estimate for 'Total Accounts' stands at 16.92 million. Compared to the current estimate, the company reported 16.01 million in the same quarter of the previous year.Analysts' assessment points toward 'Total HSA cash' reaching $17.67 billion. Compared to the current estimate, the company reported $15.85 billion in the same quarter of the previous year.The combined assessment of analysts suggests that 'HSAs Accounts' will likely reach 10.05 million. Compared to the present estimate, the company reported 9.1 million in the same quarter last year.View all Key Company Metrics for HealthEquity here>>>Over the past month, shares of HealthEquity have returned +18.4% versus the Zacks S&P 500 composite's +6.7% change. Currently, HQY carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HealthEquity, Inc. (HQY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: HealthEquity und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf HealthEquity

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf HealthEquity

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu HealthEquity Inc

Wer­bung

Analysen zu HealthEquity Inc

DatumRatingAnalyst
07.02.2019HealthEquity BuyChardan Capital Markets
20.03.2018HealthEquity BuyChardan Capital Markets
06.12.2017HealthEquity BuyChardan Capital Markets
07.06.2017HealthEquity BuyChardan Capital Markets
31.03.2017HealthEquity OverweightCantor Fitzgerald
DatumRatingAnalyst
07.02.2019HealthEquity BuyChardan Capital Markets
20.03.2018HealthEquity BuyChardan Capital Markets
06.12.2017HealthEquity BuyChardan Capital Markets
07.06.2017HealthEquity BuyChardan Capital Markets
31.03.2017HealthEquity OverweightCantor Fitzgerald
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für HealthEquity Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen